Articles & Whitepapers
The medicine may be free. The tax risk is not.
Authors: Dr Romina Oxborough • Dale Bushell
Published by: Maprium & VAT IT
VAT, customs and tariffs are becoming harder to separate from the day-to-day reality of running a global Managed Access Program.
From changing EU VAT requirements to US tariffs, the way medicines move across borders can create unexpected costs, compliance risks and missed recovery opportunities.
Our latest article, produced with VAT IT, explores what pharma teams need to understand — and why tax considerations should be built into MAP planning from the outset.
Download the PDF to explore the key issues, risks and opportunities for global Managed Access Programs.
More news and blogs
Blog
New Collaboration Helps Pharmaceutical Companies Generate Greater Value from Global Managed Access Programs
Partnership combines enterprise technology with real-world evidence expertise to maximise the strategic value of Managed Access Programs.
Blog
Featured Perspective
Managed Access Programs: Building the Evidence Infrastructure for Rare Disease. Discover why MAPs are more important than ever in Rare Disease.
Take a personalized 15-minute tour
To request a demo, discuss your access challenges or learn more about Maprium, please use the secure form.